Halozyme Therapeutics (NASDAQ:HALO) Given New $72.00 Price Target at HC Wainwright

Halozyme Therapeutics (NASDAQ:HALO) had its price target boosted by HC Wainwright from $70.00 to $72.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other research firms also recently commented on HALO. Wells Fargo & Company lowered their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. JMP Securities boosted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Finally, Piper Sandler raised their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $61.11.

Halozyme Therapeutics Stock Down 0.2 %

Halozyme Therapeutics stock opened at $57.77 on Wednesday. The stock’s 50 day moving average price is $53.07 and its 200 day moving average price is $54.56. Halozyme Therapeutics has a 1-year low of $35.50 and a 1-year high of $65.53. The company has a market cap of $7.35 billion, a PE ratio of 19.13, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 179.82% and a net margin of 41.43%. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. On average, sell-side analysts predict that Halozyme Therapeutics will post 3.87 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 2.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. CBIZ Investment Advisory Services LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter worth about $29,000. Heck Capital Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $29,000. Smartleaf Asset Management LLC boosted its position in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 197 shares during the last quarter. FSC Wealth Advisors LLC purchased a new stake in Halozyme Therapeutics in the third quarter valued at approximately $65,000. Finally, Venturi Wealth Management LLC acquired a new position in Halozyme Therapeutics during the fourth quarter worth approximately $69,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.